

In response, Applicants elect the subject matter of Group I. The Examiner has further required election of a single species, for prosecution on the merits, of Claims 3, 4, 5, 6, 7, and 10, to which the claims shall be restricted if no generic claim is held to be allowable.

In response, Applicants elect to pursue the subject matter of the following species: cognitive dysfunction (claim 3), central nervous system tissue (claim 4), parenteral administration (claim 5), intravenous administration (claim 6), chronic administration (claim 7), and recombinant erythropoietin (claim 10).

Applicants respectfully request that the foregoing remarks made herein be entered into the record of the instant application. Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150.

RECEIVED
MAR 06 2002
TECH CENTER 1600/2800

Respectfully submitted,

Date: March 1, 2002

Laura A. Coruzzi 30,742

Laura A. Coruzzi (Reg. No.)

By: Eileen E. Falvey 46,097

Eileen E. Falvey (Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosures